Prognosis
Eli Lilly Covid Antibody Drug Gets FDA Emergency Clearence
- U.S. to pay Lilly $375 million for 300,000 vials of the drug
- Monoclonal antibody to be used in high-risk patients over 12
This article is for subscribers only.
Eli Lilly & Co.’s antibody therapy was granted an emergency-use authorization by U.S. drug regulators for treating Covid-19, widening access to a treatment that early data suggest is effective in keeping people infected with the coronavirus out of the hospital.
The Food and Drug Administration authorized the experimental treatment, called bamlanivimab, for use against mild-to-moderate Covid-19 in adults, including those who are 65 and older, and pediatric patients, the agency said in a statement.